Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again

US Appeals Court Denies Genentech Request For Injunction On Bevacizumab

 
• By Dean Rudge
  
Gavels
Amgen launched Mvasi on 18 July last year after Genentech was denied an injunction • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin